1-8 of 8
Edmund A. Rossi, PhD
Close
Sort by
Journal Articles

First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR-Interferon-á2b) Is Highly Toxic for Human Lymphoma Cells in Vitro .

Diane L Nordstrom, Edmund A Rossi, PhD, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD
Journal: Blood
Blood (2009) 114 (22): 1695.
https://doi.org/10.1182/blood.V114.22.1695.1695
Published: 2009
Journal Articles

A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.

Edmund A Rossi, PhD, Eric Chan, Pankaj Gupta, Ph.D, David M. Goldenberg, ScD, MD, Chien-Hsing Chang, PhD
Journal: Blood
Blood (2009) 114 (22): 3721.
https://doi.org/10.1182/blood.V114.22.3721.3721
Published: 2009
Journal Articles

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Diane L Nordstrom, David M. Goldenberg, ScD, MD
Journal: Blood
Blood (2008) 112 (11): 1590.
https://doi.org/10.1182/blood.V112.11.1590.1590
Published: 2008
Journal Articles

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Rhona Stein, PhD, Diana Pilas, Diane L Nordstrom, John Kopinski, David M. Goldenberg, ScD, MD
Journal: Blood
Blood (2008) 112 (11): 1591.
https://doi.org/10.1182/blood.V112.11.1591.1591
Published: 2008
Journal Articles

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Robert M Sharkey, Ph.D., M. Jules Mattes, Ph.D., Habibe Karacay, Ph.D., Chien-Hsing Chang, PhD, Edmund A Rossi, PhD, William J McBride, Ph.D., David M. Goldenberg, ScD, MD
Journal: Blood
Blood (2008) 112 (11): 1588.
https://doi.org/10.1182/blood.V112.11.1588.1588
Published: 2008
Journal Articles

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Edmund A. Rossi, PhD, William J. McBride, Ph.D., Diane L. Nordstrom, M.S., Preeti Trisal, M.S., Thomas M. Cardillo, Ph.D., David M. Goldenberg, M.D. Sc.D., Chien-Hsing Chang, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 1396.
https://doi.org/10.1182/blood.V110.11.1396.1396
Published: 2007
Journal Articles

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

David M. Goldenberg, ScD, MD, Robert M. Sharkey, PhD, Habibe Karacay, PhD, Chien-Hsing Chang, PhD, Edmund A. Rossi, PhD, William J. McBride, PhD
Journal: Blood
Blood (2007) 110 (11): 2344.
https://doi.org/10.1182/blood.V110.11.2344.2344
Published: 2007
Journal Articles

Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity.

Edmund A. Rossi, PhD, Michele J. Losman, Ph.D., Diane L. Nordstrom, M.S., Thomas Cardillo, Ph.D., Meiyu Loo, M.S., John Kopinski, B.S., Zhengxing Qu, Ph.D., David M. Goldenberg, Sc.D., M.D., Chien-Hsing Chang, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2495.
https://doi.org/10.1182/blood.V108.11.2495.2495
Published: 2006